ZA200305922B - Use of flumazenil in developing a drug for the treatment of alcohol dependence. - Google Patents
Use of flumazenil in developing a drug for the treatment of alcohol dependence. Download PDFInfo
- Publication number
- ZA200305922B ZA200305922B ZA200305922A ZA200305922A ZA200305922B ZA 200305922 B ZA200305922 B ZA 200305922B ZA 200305922 A ZA200305922 A ZA 200305922A ZA 200305922 A ZA200305922 A ZA 200305922A ZA 200305922 B ZA200305922 B ZA 200305922B
- Authority
- ZA
- South Africa
- Prior art keywords
- flumazenil
- treatment
- administration
- alcohol
- medicament
- Prior art date
Links
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 title claims abstract description 88
- 229960004381 flumazenil Drugs 0.000 title claims abstract description 86
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 238000011282 treatment Methods 0.000 title claims description 35
- 229940079593 drug Drugs 0.000 title abstract description 15
- 208000007848 Alcoholism Diseases 0.000 title abstract description 3
- 201000007930 alcohol dependence Diseases 0.000 title abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- 208000029650 alcohol withdrawal Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 229940049706 benzodiazepine Drugs 0.000 description 8
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 7
- 229960004414 clomethiazole Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 150000001557 benzodiazepines Chemical class 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000019156 vitamin B Nutrition 0.000 description 5
- 239000011720 vitamin B Substances 0.000 description 5
- 229940046001 vitamin b complex Drugs 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 102000004300 GABA-A Receptors Human genes 0.000 description 4
- 108090000839 GABA-A Receptors Proteins 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229960004526 piracetam Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000857916 Gerra Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012225 Delirium tremens Diseases 0.000 description 1
- 102000017934 GABA-B receptor Human genes 0.000 description 1
- 108060003377 GABA-B receptor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- -1 amino acids amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000000749 benzodiazepine receptor blocking agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 229940085047 disulfiram 250 mg Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 231100000663 medical toxicology Toxicity 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200100106 | 2001-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200305922B true ZA200305922B (en) | 2004-08-02 |
Family
ID=8496426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200305922A ZA200305922B (en) | 2001-01-17 | 2002-01-10 | Use of flumazenil in developing a drug for the treatment of alcohol dependence. |
Country Status (23)
Country | Link |
---|---|
US (2) | US7348321B2 (zh) |
EP (1) | EP1374952B1 (zh) |
JP (2) | JP2004519461A (zh) |
KR (1) | KR100712570B1 (zh) |
CN (1) | CN1486205A (zh) |
AT (1) | ATE338575T1 (zh) |
AU (1) | AU2002226427B2 (zh) |
BR (1) | BR0206549A (zh) |
CA (1) | CA2433833C (zh) |
CR (1) | CR7049A (zh) |
CY (1) | CY1107500T1 (zh) |
DE (1) | DE60214527T2 (zh) |
DK (1) | DK1374952T3 (zh) |
ES (1) | ES2269661T3 (zh) |
HK (1) | HK1061661A1 (zh) |
IL (1) | IL156798A0 (zh) |
MX (1) | MXPA03006411A (zh) |
NZ (2) | NZ527583A (zh) |
PT (1) | PT1374952E (zh) |
RU (1) | RU2300378C2 (zh) |
UA (1) | UA78199C2 (zh) |
WO (1) | WO2002056964A1 (zh) |
ZA (1) | ZA200305922B (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
US20060172996A1 (en) * | 2005-02-03 | 2006-08-03 | Halikas James A | Method of preventing relapse in the abstinent substance dependent individual |
US20060172998A1 (en) * | 2005-02-03 | 2006-08-03 | Halikas James A | Method of preventing relapse in the abstinent substance dependent individual |
WO2006110642A2 (en) | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
US20060263304A1 (en) * | 2005-05-23 | 2006-11-23 | Halikas James A | Method of controlling alcohol intake and reversing alcohol effects |
SG183696A1 (en) | 2007-08-06 | 2012-09-27 | Biotie Therapies Inc | Medicaments comprising nepicastat for use in treating dependence on a substance |
WO2009027564A1 (es) * | 2007-08-08 | 2009-03-05 | Legarda Ibanez Juan Jose | Uso y métodos de uso de un antagonista del receptor (5-ht3) de la serotonina3 y un modulador selectivo de los canales de cloruro para el tratamiento de la adicción a o la dependencia de fármacos/drogas o trastornos del sistema nervioso central |
EP2398475B1 (en) * | 2009-02-20 | 2017-12-13 | Palmaya Pty Ltd | Pharmaceutical preparation and delivery system |
US8387589B2 (en) * | 2009-04-29 | 2013-03-05 | Marine Canada Acqusition Inc. | Position sensor for an output shaft used in a shift and throttle system |
US8347859B2 (en) * | 2009-04-29 | 2013-01-08 | Marine Canada Acquisition Inc. | Automatic throttle calibration in a marine vessel |
US20100280684A1 (en) * | 2009-04-29 | 2010-11-04 | Pierre Garon | Synchronization of shift and throttle controls in a marine vessel |
US8930050B2 (en) * | 2009-04-29 | 2015-01-06 | Marine Canada Acquisition Inc. | Method and system for increasing or decreasing engine throttle in a marine vessel |
US8845490B2 (en) | 2010-02-10 | 2014-09-30 | Marine Canada Acquisition Inc. | Method and system for delaying shift and throttle commands based on engine speed in a marine vessel |
US8182396B2 (en) * | 2010-02-10 | 2012-05-22 | Marine Canada Acquisition In.c | Method and system for delaying shift and throttle commands based on engine speed in a marine vessel |
US8406944B2 (en) * | 2010-02-10 | 2013-03-26 | Pierre Garon | Control system and method for starting and stopping marine engines |
CA2827336C (en) | 2011-02-23 | 2016-01-26 | Coeruleus Ltd. | Flumazenil complexes, compositions comprising same and uses thereof |
RU2468799C1 (ru) * | 2011-08-03 | 2012-12-10 | Общество с ограниченной ответственностью "Урал Крафт" | Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5519017A (en) * | 1990-03-29 | 1996-05-21 | Lts Lohmann Therapie-Systeme Gmbh + Co. Kg | Pharmaceutic formulation for the treatment of alcoholism |
SE9100860D0 (sv) * | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
GB9420010D0 (en) * | 1994-10-01 | 1994-11-16 | Marck Sharp & Dohme Limited | Nucleic acids |
US20030176456A1 (en) * | 2001-12-21 | 2003-09-18 | June Harry L. | Methods for reducing alcohol cravings in chronic alcoholics |
US6740677B2 (en) * | 2002-08-19 | 2004-05-25 | Hong Xue | Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids |
-
2002
- 2002-01-10 CA CA002433833A patent/CA2433833C/en not_active Expired - Fee Related
- 2002-01-10 WO PCT/ES2002/000008 patent/WO2002056964A1/es active IP Right Grant
- 2002-01-10 ES ES02716090T patent/ES2269661T3/es not_active Expired - Lifetime
- 2002-01-10 KR KR1020037009461A patent/KR100712570B1/ko not_active IP Right Cessation
- 2002-01-10 NZ NZ527583A patent/NZ527583A/xx not_active IP Right Cessation
- 2002-01-10 JP JP2002557469A patent/JP2004519461A/ja active Pending
- 2002-01-10 AU AU2002226427A patent/AU2002226427B2/en not_active Ceased
- 2002-01-10 EP EP02716090A patent/EP1374952B1/en not_active Expired - Lifetime
- 2002-01-10 PT PT02716090T patent/PT1374952E/pt unknown
- 2002-01-10 CN CNA028038029A patent/CN1486205A/zh active Pending
- 2002-01-10 MX MXPA03006411A patent/MXPA03006411A/es active IP Right Grant
- 2002-01-10 BR BR0206549-5A patent/BR0206549A/pt not_active Application Discontinuation
- 2002-01-10 DK DK02716090T patent/DK1374952T3/da active
- 2002-01-10 AT AT02716090T patent/ATE338575T1/de active
- 2002-01-10 DE DE60214527T patent/DE60214527T2/de not_active Expired - Lifetime
- 2002-01-10 ZA ZA200305922A patent/ZA200305922B/en unknown
- 2002-01-10 RU RU2003125274/15A patent/RU2300378C2/ru not_active IP Right Cessation
- 2002-01-10 NZ NZ539400A patent/NZ539400A/en not_active IP Right Cessation
- 2002-01-10 IL IL15679802A patent/IL156798A0/xx unknown
- 2002-10-01 UA UA2003087768A patent/UA78199C2/uk unknown
-
2003
- 2003-07-15 US US10/621,229 patent/US7348321B2/en active Active
- 2003-08-06 CR CR7049A patent/CR7049A/es unknown
-
2004
- 2004-07-02 HK HK04104732A patent/HK1061661A1/xx not_active IP Right Cessation
-
2006
- 2006-11-14 CY CY20061101651T patent/CY1107500T1/el unknown
-
2008
- 2008-02-06 US US12/026,643 patent/US20080132492A1/en not_active Abandoned
- 2008-04-28 JP JP2008116697A patent/JP2008201796A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL156798A0 (en) | 2004-02-08 |
DE60214527D1 (de) | 2006-10-19 |
CN1486205A (zh) | 2004-03-31 |
AU2002226427B2 (en) | 2006-11-16 |
WO2002056964A1 (es) | 2002-07-25 |
KR20040020046A (ko) | 2004-03-06 |
US7348321B2 (en) | 2008-03-25 |
UA78199C2 (en) | 2007-03-15 |
CR7049A (es) | 2008-02-20 |
CA2433833C (en) | 2009-06-02 |
CY1107500T1 (el) | 2013-03-13 |
NZ527583A (en) | 2006-03-31 |
ATE338575T1 (de) | 2006-09-15 |
EP1374952B1 (en) | 2006-09-06 |
DK1374952T3 (da) | 2007-01-02 |
US20080132492A1 (en) | 2008-06-05 |
MXPA03006411A (es) | 2004-12-02 |
EP1374952A1 (en) | 2004-01-02 |
BR0206549A (pt) | 2004-02-25 |
HK1061661A1 (en) | 2004-09-30 |
RU2300378C2 (ru) | 2007-06-10 |
CA2433833A1 (en) | 2002-07-25 |
JP2008201796A (ja) | 2008-09-04 |
PT1374952E (pt) | 2006-12-29 |
KR100712570B1 (ko) | 2007-05-02 |
NZ539400A (en) | 2006-04-28 |
ES2269661T3 (es) | 2007-04-01 |
JP2004519461A (ja) | 2004-07-02 |
RU2003125274A (ru) | 2005-01-20 |
US20040092509A1 (en) | 2004-05-13 |
DE60214527T2 (de) | 2007-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080132492A1 (en) | Use of Flumazenil in the Production of a Drug for the Treatment of Alcohol Dependency | |
US20190388435A1 (en) | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction | |
US20190262359A1 (en) | Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction | |
US20070142364A1 (en) | Flumazenil for the Treatment of Cocaine Dependency | |
JP2004519461A5 (zh) | ||
JP2004521904A5 (zh) | ||
AU2006246490B8 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
BERLIN | FREDERICK W. SCHAERF | |
AU2006200922A1 (en) | Use of flumazenil to produce a medicament for the treatment of cocaine dependency |